Submission of outcome of Board Meeting held on 12th May, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Astal Laboratories Ltd's Board approved the allotment of 14,70,000 equity shares (face value Rs. 10 each) at Rs. 40 per share to 11 non-promoter strategic investors upon conversion of warrants. The company received Rs. 4.41 crore (remaining 75% of issue price) from this conversion. These warrants were originally allotted on 27th November 2024 following shareholder approval at the AGM held on 05th August 2024, with BSE in-principle approval obtained on 14th November 2024. Post-allotment, the company's paid-up equity capital increased from Rs. 42.28 crore to Rs. 43.69 crore, with total shares increasing from 4.22 crore to 4.37 crore.
This preferential allotment to non-promoters results in dilution of existing shareholders' stake by approximately 3.5%. The capital raise of Rs. 4.41 crore strengthens the company's cash position, but the increased share count may exert mild downward pressure on earnings per share.